Quick Answer
Xeris Biopharma Holdings, Inc. reported Total Revenue of $291.85 million for fiscal year 2025.
Xeris Biopharma Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $291.85M +43.7% |
$203.07M +23.9% |
$163.91M +48.7% |
$110.25M +122.3% |
$49.59M +142.7% |
$20.43M |
| Revenue (ASC 606) | $291.85M +43.7% |
$203.07M +23.9% |
$163.91M +48.7% |
$110.25M +122.3% |
$49.59M +146.0% |
$20.16M |
| Net Income | $554.0K +101.0% |
-$54.84M +11.9% |
-$62.26M +34.2% |
-$94.66M +22.9% |
-$122.72M -34.7% |
-$91.14M |
| Diluted EPS | $0.00 +100.0% |
-$0.37 +17.8% |
-$0.45 +35.7% |
-$0.70 +54.8% |
-$1.55 | — |
| Total Assets | $383.53M +18.7% |
$323.06M +0.1% |
$322.60M -6.4% |
$344.52M +13.2% |
$304.36M +91.2% |
$159.15M |
| Cash and Equivalents | $111.04M +55.0% |
$71.62M +6.2% |
$67.45M -44.7% |
$121.97M +81.3% |
$67.27M +78.9% |
$37.60M +92.6% |
| Long-Term Debt | $220.34M +1.5% |
$217.01M +13.7% |
$190.93M +2.1% |
$187.07M +112.4% |
$88.07M +1.2% |
$87.02M |
| Stockholders Equity | $13.69M +146.2% |
-$29.61M -336.7% |
-$6.78M -115.0% |
$45.19M -52.6% |
$95.23M +182.1% |
$33.76M +133.9% |
| R&D Expense | $31.16M +21.9% |
$25.56M +14.4% |
$22.34M +6.6% |
$20.97M -16.7% |
$25.16M +20.3% |
$20.92M |
| Operating Income | $24.90M +174.0% |
-$33.65M +23.5% |
-$44.01M +46.3% |
-$81.94M +28.8% |
-$115.16M -37.8% |
-$83.55M |
| Shares Outstanding | 166.22M +11.2% |
149.43M +8.2% |
138.13M +1.4% |
136.27M +9.1% |
124.87M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $74.38M | +37.1% | +4.0% |
| Revenue (ASC 606) | September 30, 2025 | $74.38M | +37.1% | +4.0% |
| Net Income | September 30, 2025 | $621.0K | +103.9% | +132.2% |
| Diluted EPS | September 30, 2025 | $0.00 | +100.0% | +100.0% |
| Total Assets | September 30, 2025 | $370.19M | +15.3% | +10.6% |
| Cash and Equivalents | September 30, 2025 | $91.60M | +54.6% | +54.5% |
| Long-Term Debt | September 30, 2025 | $219.47M | +1.5% | +0.4% |
| Stockholders Equity | September 30, 2025 | -$861.0K | +97.0% | +95.5% |
| R&D Expense | September 30, 2025 | $7.48M | +27.1% | -7.1% |
| Operating Income | September 30, 2025 | $6.73M | +152.2% | +50.2% |
| Gross Profit | September 30, 2021 | $7.84M | +18.5% | +18.5% |
| Shares Outstanding | September 30, 2025 | 165.53M | +11.1% | +2.7% |
- Xeris Biopharma Holdings, Inc. reported Total Revenue of $291.85 million for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +43.7% in Total Revenue compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Revenue (ASC 606) of $291.85 million for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +43.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Net Income of $554.0 thousand for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +101.0% in Net Income compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +100.0% in Diluted EPS compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Total Assets of $383.53 million for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +18.7% in Total Assets compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Cash and Equivalents of $111.04 million for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +55.0% in Cash and Equivalents compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Long-Term Debt of $220.34 million for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +1.5% in Long-Term Debt compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Stockholders Equity of $13.69 million for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +146.2% in Stockholders Equity compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported R&D Expense of $31.16 million for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +21.9% in R&D Expense compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Operating Income of $24.90 million for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +174.0% in Operating Income compared to the prior fiscal year.
- Xeris Biopharma Holdings, Inc. reported Shares Outstanding of 166.22 million shares for fiscal year 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +11.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: